Five-Year Transcatheter Aortic Valve Replacement Outcomes in Chronic Hemodialysis vs. Non-Hemodialysis Patients Using Balloon-Expandable Devices

Abstract

to include hemodialysis (HD) patients in 2021. However, the long-term effectiveness of TAVR in managing the lives of HD patients remains unexplored. The aim of this study was to investigate the mid-term outcomes of TAVR, including severe SVD, in Japanese HD patients treated for AS with the SAPIEN XT (XT) or SAPIEN 3 (S3) compared with non-HD patients. Methods Patient SelectionThis retrospective single-center observational study included patients with severe AS who underwent TAVR using XT or S3 at Osaka University Hospital between May 2010 and April 2022. As shown in Figure 1, patients treated with the first-generation balloon-expandable SAPIEN (Edwards Lifesciences) or other TAV devices, those who